Introduction {#s1}
============

Worldwide, respiratory infection caused by *Pseudomonas aeruginosa* is one of the most critical healthcare burdens, with six million hospital admissions and over four million deaths annually \[[@C1], [@C2]\]. In people with a weakened immune system, *P. aeruginosa* can cause acute respiratory infection leading to septicaemia and consequent fatality. In patients with cystic fibrosis (CF) and non-CF bronchiectasis, chronic life-threatening *P. aeruginosa* infections and inflammation lead to a progressive deterioration of pulmonary function \[[@C3], [@C4]\]. Despite the use of antibiotics, the control of *P. aeruginosa* infection remains perilously fragile owing to the rapid emergence of antibiotic resistance \[[@C5]--[@C7]\]. Thus, *P. aeruginosa* infections represent an especially relevant therapeutic challenge with an urgent need for the implementation of novel antimicrobial agents.

An essential prerequisite for drug development is the assessment of both safety and efficacy in animal models that mimic human disease. Although there are established guidelines that specify appropriate animal models and parameters relevant for assessing antibiotic safety, there is a lack of well-accepted guidelines for efficacy testing \[[@C8], [@C9]\]. The most commonly used animal model for evaluating the efficacy of antimicrobial agents against *P. aeruginosa* reproduces the acute respiratory infection in immunocompetent or neutropenic mice \[[@C10], [@C11]\]. However, these models are characterised by a rapid disease course and, while useful as acute respiratory infection models, they lack any characteristics of the events triggered in an established chronic infection. Furthermore, the use of neutropenic mice does not allow the host response to be assessed as a potential determinant of drug efficacy.

Although mouse models of chronic *P. aeruginosa* pneumonia have been generated to mimic the advanced stage of lung pathology in humans \[[@C10], [@C12]--[@C15]\], these models are technically more complicated than acute infections and pose several challenges. Chronic infection in these models is usually established by including bacterial cells in immobilising agents where they appear to grow in microcolonies under micro-aerobic/anaerobic conditions, as they do in the mucus of CF patients \[[@C16]\]. These models present major challenges related to the low *P. aeruginosa* burden and percentage of infected mice weeks after infection \[[@C12]\]. Although they are useful in evaluating the impact of repeated administrations in the initiation and progression of the chronic infection, these models have elevated preclinical costs. Because they are not used systematically and specifically on a preclinical platform that supports antibacterial efficacy testing, their predictive value has not been fully established. More importantly, it is unclear whether the use of a model of chronic infection in antibiotic efficacy testing against *P. aeruginosa* is advantageous and necessary compared to the acute infection model. In addition, the impact that the route of administration and the treatment schedule might have in drug efficacy is largely unknown.

In this study, we aim to define the differences between mouse models and treatment regimens in the efficacy of two marketed antibacterial drugs of the aminoglycosides and polymyxin classes, tobramycin (TOB) and colistin (COL) respectively. We designed the study to 1) evaluate treatment efficacy in murine models of acute and chronic *P. aeruginosa* respiratory infection; 2) determine if administration routes have an impact on pathogen clearance and host response using aerosol (*aero*), intranasal (*i.n.*) and subcutaneous (*s.c.*) delivery; and 3) determine if different treatment schedules affect efficacy by comparing treatment administered soon after infection to treatment administered during chronic colonisation.

Methods {#s2}
=======

Ethics statement {#s2a}
----------------

Animal studies adhered to the Italian Ministry of Health guidelines for the use and care of experimental animals (IACUC \#733 and \#878). Research with the *P. aeruginosa* multidrug-resistant (MDR)-RP73 isolate from a CF individual and storage of biological materials were approved by the Ethics Commission of Hannover Medical School, Germany.

Bacterial strains {#s2b}
-----------------

*P. aeruginosa* strains included PAO1 and MDR-RP73 strains isolated from a CF patient\'s airways. Minimum inhibitory concentrations (MICs) of TOB and COL were previously determined ([supplementary table S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)) \[[@C17]\].

Mouse model {#s2c}
-----------

Immunocompetent C57BL/6NCrlBR male mice (8--10 weeks; Charles River Laboratories, Calco, Italy) were challenged with 1×10^6^ colony-forming units (CFUs) of the planktonic PAO1 strain for acute infection or 5×10^5^ CFUs of the MDR-RP73 strain embedded in agar beads for chronic infection by intratracheal administration \[[@C12]--[@C14]\]. Mice were treated with TOB, COL or vehicle (water) by local administration using a Penn-Century MicroSprayer® Aerosoliser (*aero*) or by *i.n.* or systemic *s.c.* administration ([figure 1](#F1){ref-type="fig"}). Body weight was monitored daily. Lung CFUs and cell counts in the bronchoalveolar lavage fluid (BALF) were analysed as described previously \[[@C13], [@C18], [@C19]\]. Cytokine/chemokine levels were measured in the supernatant of lung homogenates by Bioplex Assay (Bio-Rad Laboratories, Segrate, Italy). Pharmacokinetic (PK) profiles of TOB and COL in the lungs and plasma of *P. aeruginosa*-infected mice were evaluated by high-performance liquid chromatography--tandem mass spectrometry. Additional details in accordance with the Animal Research: Reporting of *In Vivo* Experiments guidelines \[[@C20]\] are reported in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials).

![A schematic representation of the antibiotic treatment schedule and analysis in murine models of acute and chronic *Pseudomonas aeruginosa* infection. At day 0, mice were infected with *P. aeruginosa* planktonic cells to mimic acute infection or with *P. aeruginosa* embedded in agar beads to achieve long-term chronic infection. In the acute infection model, the treatment schedule used with the antibiotics was a single dose administered 5 min after infection by aerosol, intranasal or subcutaneous routes. In the chronic infection model, the treatment started 5 min ("early" treatment) or 7 days ("late" treatment) after infection, with repeated daily doses for 7 days. Read-outs of the disease progression were body weight changes, colony-forming units (CFUs), total and differential cells, and cytokines/chemokines assayed at the time of death (at 6 h for acute infection or after 7 days of treatment for chronic infection). d: days; BALF: bronchoalveolar lavage fluid.](ERJ-02456-2018.01){#F1}

Statistics {#s2d}
----------

Statistical analyses were performed with GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA) using a two-way ANOVA with Bonferroni\'s multiple comparison test for body weight changes and one-way ANOVA with Bonferroni\'s multiple comparison test for the other readouts. Outlier data, identified by Grubbs' test, were excluded from the analysis.

Results {#s3}
=======

Treatment efficacy is affected by the route of administration and type of antibiotic in acute *P. aeruginosa* lung infection {#s3a}
----------------------------------------------------------------------------------------------------------------------------

C57BL/6NCrlBR mice were challenged with the planktonic *P. aeruginosa* PAO1 strain by intratracheal inoculation to induce acute infection. Local treatment *via* the *aero* or *i.n.* route with 2 mg·kg^−1^ TOB or 1 mg·kg^−1^ COL and systemic treatment *via* the *s.c.* route with 20 mg·kg^−1^ TOB or 10 mg·kg^−1^ COL started soon (5 min) after infection ([figure 1](#F1){ref-type="fig"}). TOB and COL were dosed to keep the same dose to MIC ratio ([supplementary table S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)) and local to systemic ratio, based on previous studies \[[@C17]\]. A single dose of TOB was significantly effective at 6 h post-treatment, with a 4-log~10~ reduction in lung CFUs on *aero* administration and a 3-log~10~ reduction on *s.c.* administration when compared to CFUs observed with vehicle ([figure 2a](#F2){ref-type="fig"}). It is worth noting that TOB administered *via* either the *aero* or *s.c.* route was able to completely clear the infection in at least half of the treated mice ([supplementary table S2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)). TOB displayed limited ability for bacterial clearance and low efficacy following *i.n.* administration, with a 1-log~10~ CFU reduction compared to CFUs observed with vehicle. COL was generally less effective than TOB in reducing the bacterial burden ([figure 2b](#F2){ref-type="fig"}). COL-treated mice showed a significantly reduced bacterial burden in the lungs, with a 2-log~10~ CFU reduction after *aero* and *s.c.* administration compared to CFUs observed with vehicle, but complete clearance was not observed. No reduction in lung CFUs was observed with COL following *i.n.* administration. In summary, in acute infection, both TOB and COL treatments administered *via* the *aero* and *s.c.* routes reduced bacterial burden, with COL being less effective than TOB. Administration *via* the *i.n.* route was the least effective of all three routes, with no demonstrable efficacy for COL.

![Efficacy and pharmacokinetics of tobramycin (TOB) (a, c, e, g) and colistin (COL) (b, d, f, h) in a mouse model of acute *Pseudomonas aeruginosa* airway infection. C57BL/6 male mice (aged 8--10 weeks) received intratracheal inoculations with 1×10^6^ colony-forming units (CFUs) of planktonic PAO1. 5 min after infection, 2 mg·kg^−1^ TOB, 1 mg·kg^−1^ COL or vehicle was administered *via* an aerosoliser (*aero*) or the intranasal (*i.n.*) route. Alternatively, 20 mg·kg^−1^ TOB, 10 mg·kg^−1^ COL or vehicle was administered *via* the subcutaneous (*s.c.*) route. a--h) After 6 h, the mice were killed, bronchoalveolar lavage fluid (BALF) was collected, and the lungs were excised, homogenised and plated on tryptic soy agar to determine the bacterial burden (a, b). Each dot represents CFUs per lung from one mouse, and horizontal lines represent the median values. c, d) For pharmacokinetics analysis, mice were killed 5 min, 6 h and 24 h after treatment, and the concentration of antibiotics was measured in the lung and plasma ([supplementary figure S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)). The limits of quantification (LOQs) are indicated. e, f) Total cell and g, h) neutrophil counts were performed in BALF. Data are presented as mean±[sem]{.smallcaps} pooled from two independent experiments (n=7--8 for efficacy, and n=4--8 for pharmacokinetics). \*: p\<0.05; \*\*: p\<0.01; \*\*\*\*: p\<0.0001.](ERJ-02456-2018.02){#F2}

To interpret these results further, we examined the PK profiles of TOB and COL in the lungs and plasma of *P. aeruginosa*-infected mice. A large quantity of TOB was concentrated and retained in the lung following both local (*aero* or *i.n.*) and systemic (*s.c.*) administration for up to 24 h after administration ([figure 2c](#F2){ref-type="fig"}). These data support the study design and the local to systemic ratios. In contrast, COL concentration in the lung was significantly higher following *aero* administration than with *s.c.* or *i.n.* administration ([figure 2d](#F2){ref-type="fig"}). When viewed in relation to the decreased efficacy of TOB and COL ([figure 2a](#F2){ref-type="fig"}, b), these findings do not support a direct correlation between efficacy (CFUs per lung) and drug concentration in the lung (PK). As expected, plasma concentrations of both TOB and COL were significantly higher with systemic (*s.c.*) than with local (*aero* or *i.n.*) administration ([supplementary figure S1a and b](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)).

To define the effect of TOB and COL on the airway inflammatory response, we measured leukocyte recruitment in the BALF and cytokine/chemokine concentrations in lung homogenates. 6 h after acute PAO1 infection, mice treated with TOB by the *aero* or *s.c.* routes had fewer total cell counts ([figure 2e](#F2){ref-type="fig"}) than vehicle-treated mice, indicating a reduction in inflammation. Although COL was generally less effective than TOB in terms of bacterial burden reduction, it influenced the recruitment of leukocytes in the BALF following *aero* or *s.c.* administration ([figure 2f](#F2){ref-type="fig"}). Neutrophil counts decreased after both TOB ([figure 2g](#F2){ref-type="fig"}) and COL ([figure 2h](#F2){ref-type="fig"}) treatments *via* the *aero* and *s.c.* routes but were unaffected by treatment *via* the *i.n.* route. Macrophage counts remained unchanged following *aero* or *i.n.* administration but increased after *s.c.* treatment with both TOB and COL ([supplementary figure S2a, b](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)).

Cytokine/chemokine profiles showed that granulocyte colony-stimulating factor (G-CSF) and keratinocyte chemoattractant (KC) were consistently and significantly reduced in lungs of mice treated with both TOB and COL by *aero* and *s.c.* administration ([table 1](#TB1){ref-type="table"}). Additionally, macrophage inflammatory protein-1β (MIP-1β) and tumour necrosis factor-α (TNF-α) were significantly reduced by both TOB and COL treatments, although to a lesser extent. Reduction of these cytokines/chemokines to a similar extent with both TOB and COL, despite COL displaying lower efficacy (CFUs per lung) than TOB, suggests the lack of a direct correlation between the cytokine/chemokine response and bacterial burden. Other cytokines/chemokines that were affected by the type of antibiotic and route of administration included interleukin (IL)-1α, IL-6, IL-12p70, granulocyte--macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), MIP-1α and RANTES.

###### 

Cytokine/chemokine concentrations following acute *Pseudomonas aeruginosa* airway infection and antibiotic treatment

                  **Concentration pg·500 µg^−1^**                                                                                                                                
  -------------- --------------------------------- --------------------- ----------------- ------------------------ ----------------- ------------------------ ----------------- --------------------
  **IL-1α**                 76.65±0.40                  79.00±8.43        **87.51±10.76**      **60.14±5.34\***      **89.22±3.69**     **32.12±0.80\*\*\***    **71.86±10.94**   **39.26±4.19\*\***
  **IL-2**                   6.23±4.01                   6.62±0.59           5.96±0.45            5.99±0.16             6.18±0.42            6.43±0.15             6.18±0.24          6.01±0.19
  **IL-3**                   1.49±0.17                   1.20±0.06           1.33±0.14            1.23±0.07             1.30±0.05            1.27±0.09             1.19±0.07          1.09±0.07
  **IL-4**                   3.37±0.23                   2.76±0.19           3.10±0.34            2.62±0.22             2.84±0.23            2.21±0.21             2.33±0.22          2.09±0.15
  **IL-5**                   5.76±0.62                   6.77±0.67           5.53±0.42            4.46±0.17           **5.30±0.18**      **9.69±1.43\*\***         4.49±0.51          3.91±0.35
  **IL-6**                **51.96±10.57**            **10.75±1.27\***     **80.74±18.29**   **6.30±0.80\*\*\*\***    **95.96±19.19**   **8.90±0.78\*\*\*\***      37.55±9.90          9.70±1.02
  **IL-10**                 11.33±1.52                  10.25±1.14           9.58±0.97            9.00±0.82             9.33±0.52            9.17±0.79             8.04±0.53          7.67±0.52
  **IL-12p40**              31.46±1.55                  30.80±5.78          36.57±3.54            27.28±2.68           27.85±2.55            19.97±0.30           28.26±2.45          22.96±2.37
  **IL-12p70**              25.33±2.34                  18.09±1.76        **28.70±3.09**      **18.24±1.29\*\***     **26.86±2.00**     **16.65±1.00\*\*\***    **22.83±1.67**     **17.73±1.18\***
  **IL-17A**                 5.54±1.20                   4.40±0.66           6.30±1.08            4.88±0.32             4.59±0.55            6.17±0.45             4.63±0.66          4.95±0.42
  **Eotaxin**              **2036±365**               **1112±180\***       **2353±192**      **778±42.52\*\*\***        2197±293              1307±276           **1842±297**      **1011±82.36\***
  **G-CSF**                **366±62.42**            **77.16±11.46\*\***    **516±92.23**    **43.44±8.56\*\*\*\***     **586±100**     **38.87±1.83\*\*\*\***    **279±49.68**     **52.66±8.57\***
  **GM-CSF**              **36.32±5.24**             **20.27±0.86\***     **34.34±3.62**       **20.10±0.64\***      **36.27±3.73**      **18.45±0.73\*\***       25.85±3.67          18.36±1.21
  **IFN-γ**                 26.45±0.74                  28.33±2.96          25.70±1.09            26.42±0.70           25.71±2.00            24.20±0.86           23.94±1.48          26.53±3.42
  **KC**                   **1136±229**              **282±33.36\*\***     **1402±236**      **276±41.22\*\*\***      **1722±201**     **226±82.49\*\*\*\***      **853±145**      **365±34.11\***
  **MCP-1**                   942±206                    368±62.05         **1224±289**       **339±50.89\*\***       **1259±194**     **201±13.15\*\*\*\***        615±105           320±27.06
  **MIP-1α**               **118±16.58**             **49.68±10.51\***     **153±28.71**     **49.52±11.41\*\***      **146±32.71**     **5.88±0.12\*\*\***       69.84±5.65          23.51±3.39
  **MIP-1β**              **59.13±7.72**             **36.31±4.90\***     **67.52±6.45**      **36.21±3.00\*\***     **66.20±5.23**     **30.88±0.37\*\*\***    **57.28±7.09**     **37.61±2.16\***
  **RANTES**                 127±12.29                  85.93±13.03        **129±14.42**       **81.00±7.62\***       **127±12.48**    **46.20±1.21\*\*\*\***    **117±12.21**    **68.67±5.54\*\***
  **TNF-α**                **165±24.18**             **97.01±14.73\***     **180±22.34**      **83.42±4.56\*\***      **159±12.40**     **71.83±2.25\*\*\***     **138±17.32**    **75.77±4.71\*\***

Data are presented as mean±[sem]{.smallcaps} pooled from two independent experiments (n=4--5[)]{.smallcaps}. Statistical significance determined by one-way ANOVA with Bonferroni\'s multiple comparison test, with significant differences between treatment and vehicle highlighted in bold. *aero*: delivery using an aerosoliser; TOB: tobramycin; *s.c.*: subcutaneous; COL: colistin; IL: interleukin; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte--macrophage colony-stimulating factor; IFN: interferon; KC: keratinocyte chemoattractant; MCP: monocyte chemoattractant protein; MIP: macrophage inflammatory protein; TNF: tumour necrosis factor; ^\#^: 2 mg·kg^−1^; ^¶^: 20 mg·kg^−1^; ^+^: 1 mg·kg^−1^; ^§^: 10 mg·kg^−1^; \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001; \*\*\*\*: p\<0.0001.

Efficacy is affected by the treatment schedule and type of antibiotic in chronic *P. aeruginosa* lung infection {#s3b}
---------------------------------------------------------------------------------------------------------------

To mimic a chronic infection similar to what is typically established in the lungs of CF patients, mice received intratracheal inoculations with the *P. aeruginosa* MDR-RP73 strain embedded in agar beads \[[@C13]\]. Administration *via* the *aero* route with 16 mg·kg^−1^ TOB or 1 mg·kg^−1^ COL ([supplementary table S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)) was started 5 min ("early" treatment; [figure 3](#F3){ref-type="fig"}) or 7 days ("late" treatment; [figure 4](#F4){ref-type="fig"}) after infection and was repeated daily for seven administrations ([figure 1](#F1){ref-type="fig"}). The doses used for *s.c.* administration were 160 mg·kg^−1^ for TOB and 10 mg·kg^−1^ for COL, based on dose to MIC ratio.

![Efficacy of "early" treatment with tobramycin (TOB) (a, c, e, g) and colistin (COL) (b, d, f, h) against *Pseudomonas aeruginosa* MDR-RP73 in a murine model of chronic lung infection. C57BL/6 male mice (aged 8--10 weeks) were infected with 5×10^5^ colony-forming units (CFUs) of MDR-RP73 embedded in agar beads by intratracheal inoculation. Treatment was started 5 min after infection, with 16 mg·kg^−1^ TOB, 1 mg·kg^−1^ COL or vehicle administered daily for 7 days *via* an aerosoliser (*aero*). Alternatively, 160 mg·kg^−1^ TOB, 10 mg·kg^−1^ COL or vehicle was administered *via* the subcutaneous (*s.c*.) route. a, b) Before each administration, mice were weighed, and the percentage change from the initial body weight was averaged for each group of mice. Data are presented as mean±[sem]{.smallcaps}. c--h) At day seven post-infection, mice were killed, bronchoalveolar lavage fluid (BALF) was collected and lungs were excised, homogenised and plated onto tryptic soy agar to determine the bacterial burden (c, d). Each dot represents CFUs per lung from one mouse, and horizontal lines represent the median values. e, f) Total cell and g, h) neutrophil counts were performed in BALF. Data are presented as the mean±[sem]{.smallcaps} pooled from two independent experiments (n=11--16). \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001; \*\*\*\*: p\<0.0001.](ERJ-02456-2018.03){#F3}

![Efficacy of "late" treatment with tobramycin (TOB) (a, c, e, g) and colistin (COL) (b, d, f, h) against *Pseudomonas aeruginosa* MDR-RP73 in a murine model of chronic lung infection. C57BL/6 male mice (aged 8--10 weeks) were infected with 5×10^5^ colony-forming units (CFUs) of MDR-RP73 embedded in agar beads by intratracheal inoculation. Treatment was started 7 days post-infection and administered daily for another 7 days with 16 mg·kg^−1^ TOB, 1 mg·kg^−1^ COL or vehicle *via* an aerosoliser (*aero*). Alternatively, 160 mg·kg^−1^ TOB, 10 mg·kg^−1^ COL or vehicle was administered *via* the subcutaneous (*s.c.*) route. a, b) Before each administration, mice were weighed, and the percentage change from the initial body weight was averaged for each group of mice. Data are presented as mean±[sem]{.smallcaps}. c--h) 7 days after the beginning of treatment, which is a total of 14 days after infection, the mice were killed, bronchoalveolar lavage fluid (BALF) was collected and lungs were excised, homogenised and plated onto tryptic soy agar to determine the bacterial burden (c, d). Each dot represents CFUs per lung from one mouse, and horizontal lines represent the median values. e, f) Total cell and g, h) neutrophil counts were performed in BALF. Data are presented as the mean±[sem]{.smallcaps} pooled from one to two independent experiments (n=5--14). \*\*: p\<0.01.](ERJ-02456-2018.04){#F4}

Over the course of 7 days of "early" treatment, TOB-treated mice exhibited significantly less loss and faster recovery of body weight than vehicle-treated mice ([figure 3a](#F3){ref-type="fig"}). Compared to vehicle-treated mice, TOB-treated mice showed a significant reduction in bacterial burden, with most of the mice clearing the infection following either *aero* or *s.c.* administration ([figure 3c](#F3){ref-type="fig"}, [supplementary table S2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)). TOB treatment significantly reduced total cell counts in the BALF, including neutrophils, when compared to treatment with vehicle, indicating a reduction in inflammation ([figure 3e](#F3){ref-type="fig"}, g). Macrophage counts were reduced in mice treated with TOB by *s.c.* administration ([supplementary figure S2a](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)). IL-1α, IL-6, IL-12p40, IL-17A, MIP-1α, RANTES and TNF-α were significantly reduced by both the *aero* and *s.c.* administration routes ([table 2](#TB2){ref-type="table"}). IL-2 and KC were significantly decreased, while IL-9 and IL-13 increased only with *aero* TOB administration. MIP-1β was significantly reduced, while IL-5 increased exclusively with *s.c.* TOB administration. Thus, when administered soon after infection, TOB was effective in reducing bacterial burden and inflammation in the lungs by both *aero* and *s.c.* routes in the chronic infection model.

###### 

Cytokine/chemokine concentrations following chronic *Pseudomonas aeruginosa* airway infection and "early" antibiotic treatment

                  **Concentration pg·500 µg^−1^**                                                                                                                  
  -------------- --------------------------------- ---------------------- ---------------- -------------------- ---------------- -------------------- ------------ -------------
  **IL-1α**               **16.58±2.86**             **7.31±0.32\*\***     **12.48±1.95**    **6.34±0.47\***       13.37±3.14         7.05±0.55        10.62±2.16    9.42±0.99
  **IL-1β**                  7.07±1.07                   8.90±0.74           6.34±0.41          7.94±1.07          7.60±1.12          6.72±0.78        6.06±0.24     5.10±0.42
  **IL-2**                 **4.33±0.09**             **7.49±0.89\*\***       5.49±0.59          5.86±0.04          6.16±0.82          6.98±0.89        4.91±0.64     6.12±0.76
  **IL-3**                   2.24±0.14                   2.52±0.18           2.44±0.17          2.89±0.07          2.36±0.20          2.45±0.32        2.13±0.13     1.86±0.07
  **IL-5**                   2.40±0.22                   2.51±0.06         **2.37±0.09**    **3.10±0.15\*\***      1.90±0.28          2.41±0.42        2.30±0.16     1.86±0.10
  **IL-6**                 **4.88±0.20**              **3.72±0.35\***      **4.45±0.34**     **3.15±0.08\***       4.38±0.43          4.01±0.56        3.54±0.16     3.88±0.10
  **IL-9**                **16.49±0.48**              **19.44±1.21\***       17.78±0.25         15.18±0.11         19.78±0.83         17.30±1.20       15.37±0.75   17.70±1.68
  **IL-10**                  9.44±0.53                   9.65±0.83           10.65±0.60         10.41±0.47         9.87±1.35          8.41±1.46        8.20±0.45     6.88±0.71
  **IL-12p40**            **68.07±6.68**            **37.67±3.42\*\*\***   **59.37±4.66**   **32.50±2.47\*\***   **64.00±7.71**   **33.56±4.20\*\***   48.88±8.11   37.17±0.71
  **IL-12p70**              26.77±2.45                   20.46±1.77          26.56±2.86         22.80±1.42         19.69±3.40         19.58±3.15       20.13±1.98   17.05±1.23
  **IL-13**               **63.53±4.62**              **81.55±4.38\***       74.97±3.83         83.52±3.25         68.18±5.55         72.57±5.84       62.75±2.25   59.91±3.96
  **IL-17A**              **15.08±2.24**             **6.01±0.17\*\***     **16.82±1.37**   **7.60±0.82\*\***    **16.02±3.68**    **6.64±0.80\***     11.98±0.50   11.04±1.41
  **Eotaxin**                637±67.26                   489±59.16           634±31.45          448±47.34        **566±22.74**    **439±17.84\*\***    534±41.19     492±27.48
  **G-CSF**                  8.50±0.95                   7.26±0.00           8.26±0.51          7.26±0.00          8.87±1.05          7.26±0.00        7.34±0.08     7.26±0.00
  **GM-CSF**                11.82±1.16                   12.22±1.47          12.28±0.64         14.61±0.91         10.59±1.56         12.10±1.66       8.92±1.16     8.80±0.94
  **IFN-γ**                 24.84±1.72                   28.83±1.84          26.24±0.94         23.24±0.36         26.11±1.59         22.86±2.28       22.99±0.70   22.46±2.47
  **KC**                  **87.11±17.82**           **22.96±3.38\*\*\***     49.11±7.62         23.85±3.43        53.02±10.71        37.19±12.03       39.43±4.81   46.16±12.49
  **MCP-1**                  150±15.00                   108±12.14           123±10.31           121±9.36          121±17.53          102±19.48         119±3.88    87.91±5.63
  **MIP-1α**              **21.19±4.72**             **3.32±0.30\*\***     **17.06±4.22**    **2.56±0.27\***     **15.59±5.05**    **2.79±0.30\***     13.46±4.03    9.73±2.49
  **MIP-1β**                27.40±1.99                   26.89±3.08        **30.13±2.78**    **20.10±0.89\***      25.59±1.04         22.49±1.34       24.24±1.56   25.19±1.37
  **RANTES**               **324±67.69**            **69.49±6.66\*\*\***   **234±33.58**     **65.56±8.55\***    **173±25.56**     **65.29±6.77\***    176±31.75     147±31.85
  **TNF-α**               **44.31±4.31**              **34.57±1.71\***     **43.25±0.31**    **32.25±2.79\***      33.59±2.13         32.79±4.05       31.41±1.09   32.12±2.86

Data are presented as mean±[sem]{.smallcaps} pooled from two independent experiments (n=4--5). Statistical significance determined by one-way ANOVA with Bonferroni\'s multiple comparison test, with significant differences between treatment and vehicle highlighted in bold. *aero*: delivery using an aerosoliser; TOB: tobramycin; *s.c.*: subcutaneous; COL: colistin; IL: interleukin; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte--macrophage colony-stimulating factor; IFN: interferon; KC: keratinocyte chemoattractant; MCP: monocyte chemoattractant protein; MIP: macrophage inflammatory protein; TNF: tumour necrosis factor; ^\#^: 16 mg·kg^−1^; ^¶^: 160 mg·kg^−1^; ^+^: 1 mg·kg^−1^; ^§^: 10 mg·kg^−1^; \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001.

Over the course of 7 days of "early" treatment, COL-treated mice lost and recovered body weight comparably to vehicle-treated mice ([figure 3b](#F3){ref-type="fig"}). Compared to treatment with the vehicle, treatment with COL by *aero* administration significantly reduced the bacterial burden ([figure 3d](#F3){ref-type="fig"}), while *s.c.* administration was not effective. Total and differential cell counts in the BALF showed a trend for reduction, which was not statistically significant for either administration route ([figure 3f](#F3){ref-type="fig"}, h and [supplementary figure S2b](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)). Accordingly, only a few cytokines/chemokines, including IL-12p40, IL-17A, eotaxin, MIP-1α and RANTES, were significantly decreased following COL treatment *via* the *aero* route, while no inflammatory mediators were reduced following *s.c.* administration ([table 2](#TB2){ref-type="table"}). Thus, when administered soon after infection, COL was effective in reducing bacterial burden and a few cytokines/chemokines in the lungs *via* the *aero* route, with no major effects observed *via* the *s.c.* route of administration in the chronic infection model.

When treatments were started 7 days after infection ("late" treatment), body weight recovery did not differ between TOB- and vehicle-treated mice ([figure 4a](#F4){ref-type="fig"}). TOB administered *via* the *aero* or *s.c.* routes failed to reduce the bacterial burden ([figure 4c](#F4){ref-type="fig"}) or cytokine/chemokine levels ([table 3](#TB3){ref-type="table"}). TOB administered *via* the *aero* route resulted in significantly higher total cell counts ([figure 4e](#F4){ref-type="fig"}, g), predominantly of macrophages ([supplementary figure S3a](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)), when compared to vehicle-treated mice. TOB administered *via* the *s.c.* route did not affect inflammation.

###### 

Cytokine/chemokine concentrations following long-term chronic *Pseudomonas aeruginosa* airway infection and "late" antibiotic treatment

                  **Concentration ng·500 µg^−1^**                                                                                  
  -------------- --------------------------------- ------------ ------------ ------------ ------------- ------------- ------------ -------------
  **IL-1α**                  8.99±0.36              10.27±0.82   9.43±0.45    10.06±1.05    9.75±1.42     8.55±0.65    9.46±1.59     9.38±1.31
  **IL-1β**                 10.00±0.59              10.64±1.21   9.59±0.79    10.91±1.46    7.67±1.01     8.67±0.49    7.52±1.02     8.78±0.34
  **IL-2**                   9.35±0.57              9.72±0.75    8.27±0.46    9.31±1.19     6.99±0.38     7.49±0.46    6.41±0.73     7.49±0.58
  **IL-3**                   3.49±0.16              3.55±0.24    3.54±0.31    3.71±0.30     2.69±0.06     2.41±0.14    2.66±0.31     2.51±0.11
  **IL-5**                   3.14±0.13              3.03±0.18    2.80±0.48    3.11±0.39     2.07±0.28     1.73±0.13    1.97±0.41     1.97±0.10
  **IL-6**                   4.00±0.22              4.40±0.09    3.67±0.12    3.99±0.32     3.83±0.29     4.26±0.49    3.66±0.23     3.89±0.29
  **IL-9**                  23.52±1.54              25.82±1.11   21.11±1.16   21.67±1.09   25.78±3.05    25.68±1.87    20.13±2.15   18.96±2.55
  **IL-10**                  8.38±0.29              8.88±0.88    7.92±1.14    8.74±1.11     5.42±0.09     4.96±0.27    6.49±0.85     5.01±0.22
  **IL-12p40**              39.70±3.41              47.98±2.46   48.51±2.99   44.41±6.32   49.13±6.01    42.23±1.70    62.52±7.26   52.31±17.13
  **IL-12p70**              24.39±2.27              28.76±2.99   21.45±3.02   23.51±3.02   15.95±2.49    16.90±1.22    15.48±2.43   12.58±1.60
  **IL-13**                 71.57±2.65              80.26±4.35   72.43±4.10   73.37±6.23   54.76±1.97    55.38±1.22    57.05±4.87   56.13±0.71
  **IL-17A**                10.31±0.52              9.25±0.66    12.59±0.51   11.31±1.10   10.64±1.53     9.70±0.30    13.76±2.29   12.26±1.74
  **Eotaxin**                451±20.08              482±48.88    397±20.91    394±28.88     390±43.02     406±30.62    431±32.80     437±42.23
  **G-CSF**                  7.73±0.37              7.36±0.00    7.36±0.00    7.36±0.00     7.36±0.00     7.99±0.52    7.36±0.00     7.36±0.00
  **GM-CSF**                12.57±1.09              12.30±0.23   9.40±1.04    12.39±1.73    7.01±0.89     6.01±0.50    6.63±1.46     3.82±0.18
  **IFN-γ**                 34.24±1.36              38.43±1.71   30.13±1.81   32.32±2.49   30.56±2.77    30.54±1.47    27.06±2.51   25.84±1.51
  **KC**                    33.99±4.66              31.75±5.09   26.09±2.53   23.63±2.23   68.44±28.38   56.86±11.86   25.93±3.22   26.60±2.28
  **MCP-1**                  139±7.78               152±19.78    129±11.02     128±6.85     137±25.13     134±16.77     112±5.99     120±7.68
  **MIP-1α**                 2.83±0.46              4.64±0.77    4.74±0.68    3.49±0.54     5.05±1.67     3.63±0.48    5.66±1.49     3.19±0.09
  **MIP-1β**                25.51±1.33              28.58±1.10   24.45±0.91   25.58±1.81   22.17±1.03    23.87±0.58    21.56±1.17   19.22±1.56
  **RANTES**                76.33±6.34              75.65±3.13   75.11±4.74   77.92±7.76   90.31±18.13   80.08±10.75    105±9.44    82.78±8.23
  **TNF-α**                 54.38±4.27              59.62±2.66   50.12±2.79   51.15±4.00   43.25±2.65    41.37±2.76    41.84±1.98   39.16±2.33

Data are presented as the mean±[sem]{.smallcaps} pooled from one to two independent experiments (n=4--5). No statistically significant differences (one-way ANOVA with Bonferroni\'s multiple comparison test) were found between antibiotics and their respective vehicle. *aero*: delivery using an aerosoliser; TOB: tobramycin; *s.c.*: subcutaneous; COL: colistin; IL: interleukin; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte--macrophage colony-stimulating factor; IFN: interferon; KC: keratinocyte chemoattractant; MCP: monocyte chemoattractant protein; MIP: macrophage inflammatory protein; TNF: tumour necrosis factor; ^\#^: 16 mg·kg^−1^; ^¶^: 160 mg·kg^−1^; ^+^: 1 mg·kg^−1^; ^§^: 10 mg·kg^−1^.

Similar to the results obtained with "late" TOB treatment, the loss or recovery of body weight ([figure 4b](#F4){ref-type="fig"}), the bacterial burden ([figure 4d](#F4){ref-type="fig"}) and inflammatory cell recruitment ([figure 4f](#F4){ref-type="fig"}, h and [supplementary figure S3b](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02456-2018.figures-only#fig-data-supplementary-materials)) did not differ between "late" COL- and vehicle-treated mice. Cytokine/chemokine profiles were unchanged between "late" COL- and vehicle-treated mice, supporting a lack of efficacy ([table 3](#TB3){ref-type="table"}). Our results indicate that treatment by TOB and COL in the chronic infection model was only effective when the antibiotics were administered soon after infection.

Discussion {#s4}
==========

Antibacterial efficacy is affected by the route of administration, type of antibiotic and infection model {#s4a}
---------------------------------------------------------------------------------------------------------

First, we used the acute infection model established by direct intratracheal administration of the planktonic reference strain PAO1 to evaluate the efficacy of the antibacterial agents TOB and COL delivered by local (*aero* or *i.n.*) or systemic (*s.c.*) routes. Our results showed that *aero* and *s.c.* administration of both TOB and COL significantly reduced the bacterial burden. In the acute infection model, efficacy was substantially reduced for both TOB and COL by *i.n.* administration, highlighting the difficulty of achieving efficacy of even potent drugs with this route. Direct instillations are preferred for local delivery of therapeutic agents into rodent lungs; however, *i.n.* administration has been reported to result in drug retention in the nasal cavities \[[@C21]\]. These observations are consistent with our PK data and other studies that demonstrated low levels of COL in the lung following *i.n.* administration \[[@C22]\]. In contrast, TOB rapidly reached the airways, indicating its markedly high penetration by *i.n.* administration. While the use of a conventional human-adapted nebuliser has shown low deposition efficiency and was, therefore, excluded from this work \[[@C23]\], the aerosoliser device used for *aero* administration is a non-invasive aerosol delivery system that ensures a rapid and good spread of molecules into the airways \[[@C24]\]. This was supported by PK profiles obtained for both TOB and COL following *aero* administration. Bacterial burden was significantly reduced by *s.c.* administration of both TOB and COL, although lower lung penetration was observed for COL than for TOB. Regarding bacterial eradication, TOB treatment by *aero* and *s.c.* administration cleared *P. aeruginosa* in the majority of mice, while COL significantly reduced the bacterial burden, although complete clearance was not achieved. Overall, our data do not fully support any direct correlation between efficacy (CFUs per lung) and drug concentration in the lung (PK), raising the question of whether other drug features or host factors may contribute.

Next, we used a chronic infection model established by direct intratracheal administration of a clinical MDR-RP73 strain embedded in agar beads. Compared to vehicle-treated animals, mice treated by local (*aero*) or systemic (*s.c.*) administration of TOB soon after infection ("early" treatment) exhibited significantly increased recovery and gain of body weight and reduced bacterial burden in the lung. In contrast, COL-treated mice did not exhibit differences in recovery and gain of body weight when compared with vehicle-treated mice. In comparison to TOB treatment that resulted in bacterial clearance in most mice when administered *via* the *aero* or *s.c*. routes, only a significant but modest decrease in bacterial burden was observed with COL treatment *via* the *aero* route, while *s.c.* administration of COL was not effective. Thus, "early" treatment with TOB was effective in both the acute and chronic infection models, while the efficacy of COL differed in the two murine models. Toxicity and potential adverse effects of repeated doses may partly explain the results obtained in the chronic infection model for COL \[[@C25], [@C26]\]. Our findings suggest that the results seen upon short-term treatment in mouse models of acute infection may not be predictive of the efficacy of the repeated treatment regimen followed in chronic infections.

Our work focused on immunocompetent C57BL/6 mice given that no significant differences have been observed in the bacterial burden between CF and non-CF mice in previous antibiotic testing procedures \[[@C17]\]. Previous data indicate that the efficacy of treatment is not influenced by the CF environment. By contrast, different bacterial strains can vary the degree of disease severity, potentially impacting on antibiotic efficacy. Our animal experiments were performed with selected *P. aeruginosa* strains, PAO1 for acute infection and MDR-RP73 for chronic infection. This limitation is mitigated somewhat by the rationale behind this selection. PAO1 is the reference strain endowed with virulence factors most relevant for acute respiratory infections such as hospital-acquired pneumoniae \[[@C27], [@C28]\]. Among several CF clinical *P. aeruginosa* isolates tested, MDR-RP73 was the most efficient in establishing chronic pneumonia in a murine model \[[@C13], [@C17], [@C29], [@C30]\], reproducing hallmarks of CF and non-CF bronchiectasis.

Antibiotic efficacy is affected by the treatment schedule in chronic infection {#s4b}
------------------------------------------------------------------------------

In patients with established chronic *P. aeruginosa* pulmonary infection, antibiotics generally fail to eradicate the bacterial pathogen. Thus, rather than eradication, treatment during advanced chronic infection focuses on preserving lung function with the resolution of periodic exacerbations \[[@C31]\]. When treatment was started 7 days post-infection ("late" treatment) in the chronic infection model, no reduction in bacterial burden or inflammation, or weight recovery was observed with either TOB or COL. The growth of *P. aeruginosa* in biofilms, which can be observed in our mouse model during advanced chronic lung infection \[[@C14]\], may explain the antibiotic inefficacy, and this phenomenon represents a significant challenge in the treatment of *P. aeruginosa*.

The inflammatory response does not strictly reflect changes in bacterial burden {#s4c}
-------------------------------------------------------------------------------

This study extended the analysis of infection to multiple host parameters that included measurement of immune cells in the BALF and cytokine/chemokine production in the lung. Although the efficacy of TOB was greater than that of COL in reducing bacterial burden in the acute infection model, COL significantly reduced the inflammatory profile in the airways, particularly the neutrophil load, and to a moderately greater extent than by TOB. This may reflect the contribution of immunomodulatory effects of antibiotics to efficacy \[[@C32], [@C33]\] and deserves further investigation with additional model systems. Assessment of cytokine/chemokine profiles revealed significantly reduced levels of G-CSF and KC in mice treated with TOB and COL by local and systemic administration. Both these immune mediators are known to be determinants of neutrophil production, differentiation and recruitment. Their reduction was independent of the antibiotic and the route of administration, suggesting that G-CSF and KC could be strong candidates for efficacy biomarkers. Other cytokines/chemokines were also affected by the type of antibiotic and the route of administration. It should be pointed out that these differences in host response did not strictly correlate with the extent of bacterial burden modulation.

In chronic pulmonary infection, when treatments were started soon after infection ("early" treatment), TOB was highly effective and attenuated the inflammatory response, particularly of neutrophils, to an even greater extent than in the acute infection model. Concentrations of diverse cytokines/chemokines, such as IL-17A and IL-6, were significantly reduced with both local and systemic administration of TOB, suggesting a complex scenario for the host response. Modulation of other cytokines/chemokines was dependent on the route of administration. For instance, KC was significantly reduced by local treatment, and MIP-1β by systemic treatment. In the case of "early" treatment with COL, the inflammatory response in terms of cells recruited in the BALF was not significantly affected, and only a significant but modest reduction in a few cytokines/chemokines was detected exclusively after local administration.

When treatments were started late after infection ("late" treatment) in the chronic infection model, neither TOB nor COL could decrease the bacterial burden or modulate the immune response. Notably, the entire panel of cytokines/chemokines remained unaffected by the antibiotics, and this result represents a significant concern for the treatment of advanced chronic *P. aeruginosa* infection.

Conclusions {#s4d}
-----------

This work responds to the need for animal models, protocols and end points to improve predictive value and clinical relevance in drug testing in accordance with European Respiratory Society task force recommendations \[[@C34]\]. So far, preclinical animal models do not satisfactorily predict the complexities of human respiratory disease, jeopardising the success of drug efficacy testing. This acquires particular relevance in respiratory infections by *P. aeruginosa*, a pathogen that is notably difficult to treat because of its striking adaptive abilities. Our results in a preclinical platform underline the importance of carefully selecting the appropriate mouse model and treatment regimen for the disease under investigation to optimise antibiotic testing ([figure 5](#F5){ref-type="fig"}). By profiling bacterial and host responses, we defined multiple end points that are critical parameters to validate the efficacy of anti-*P. aeruginosa* treatments. We showed that a combination of these procedures in disease-specific models might provide an enhanced link between preclinical testing and clinical trials. The challenge ahead is to improve these mouse models by including additional variables such as the host genetic background, polymicrobial communities and the concomitant use of other therapies \[[@C35]--[@C37]\] to further reflect the complexity of human diseases.

![Roadmap of antibacterial efficacy testing in mouse models of respiratory infection. The preclinical platform for antibacterial efficacy testing includes acute and chronic infection models and different treatment regimens. Multiple end points, including profiling of bacterial and host responses, are critical parameters to validate the efficacy of anti-*Pseudomonas aeruginosa* treatment.](ERJ-02456-2018.05){#F5}
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